SA JOURNAL OF DIABETES & VASCULAR DISEASE RESEARCH ARTICLE VOLUME 21 NUMBER 1 • November 2024 21 16. Jin JL, Cao YX, Wu LG, et al. Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. J Thorac Dis 2018; 10(11): 6137–6146. 17. Hu C, Zhang J, Liu J, et al. Discordance between the triglyceride glucose index and fasting plasma glucose or HbA1c in patients with acute coronary syndrome undergoing percutaneous coronary intervention predicts cardiovascular events: a cohort study from China. Cardiovasc Diabetol 2020; 19(1): 116. 18. Hill M A, Yang Y, Zhang L, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism 2021; 119: 154766. 19. Wu Z, Liu L, Wang W, et al. Triglyceride–glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study. Cardiovasc Diabetol 2022; 21(1): 142. 20. Jiao Y, Su Y, Shen J, et al. Evaluation of the long-term prognostic ability of triglyceride–glucose index for elderly acute coronary syndrome patients: a cohort study. Cardiovasc Diabetol 2022; 21(1): 3. 21. Guo X, Shen R, Yan S, et al. Triglyceride–glucose index for predicting repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention. Cardiovasc Diabetol 2023; 22(1): 43. 22. Zhu Y, Liu K, Chen M, et al. Triglyceride–glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents. Cardiovasc Diabetol 2021; 20(1): 137. 23. Abderrahman H A, Al-Abdallat I M, Idhair A K. Age threshold for proper definition of premature coronary artery disease in males. J Forensic Leg Med 2018; 58: 45–49. 24. Gerrits A J, Koekman C A, Van Haeften T W, et al. Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin. Diabetes 2010; 59(6): 1487–1495. 25. Wu S, Liu W, Ma Q, et al. Association between insulin resistance and coronary plaque vulnerability in patients with acute coronary syndromes: insights from optical coherence tomography. Angiology 2019; 70(6): 539–546. Insulin, metformin combo helps heal diabetic foot ulcers People with chronic diabetic foot ulcers could soon have a new way to treat their wounds for faster healing and fewer hospital stays, according to researchers from Michigan State University and South Shore Hospital, who suggest that the combination of two common diabetes drugs, injectable insulin and orally administered metformin, actually increases the amount of metformin at the wound site. As metformin can accelerate wound healing, this could be welcome news for the 18.6 million people worldwide who develop a diabetic foot ulcer (DFU) in their lifetimes, reports News-Medical.net. ‘When we collected human exudates from diabetic foot ulcers and analysed their composition, one of the things that we noticed in the composition of the exudates, which has not been observed anywhere else, was the presence of metformin,’ said Morteza Mahmoudi, associate professor, Department of Radiology and Precision Health Programme, MSU College of Human Medicine. ‘Until now, pharmacological studies had not found an interaction between insulin and metformin,’ he added. ‘Our study shows that there could be at least an indirect role of consuming both insulin and metformin in a way that metformin can end up in a wound area where it enhances the body’s capacity to heal.’ Mahmoudi and co-researcher Lisa Gould, a plastic surgeon and wound-care clinician at South Shore Hospital and a clinical associate professor of medicine at Brown University, recently published an article in ACS Pharmacology and Translational Science that details the previously unheard-of connection between insulin and metformin in DFU exudates. ‘Our findings can affect how clinicians approach healing chronic wounds,’ Mahmoudi said. ‘For example, if a patient gets a wound, the synergistic role of insulin and metformin could be helpful. Additionally, wound dressing developers need to consider the interactions of anything they put on top of wounds with exudates. Exudates can interact with the wound dressings and affect their safety and therapeutic efficacy. Additional research will be evaluating this’” Published in ACS Pharmacology and Translational Science on 4 September 2024 TELMISARTAN/ AMLODIPINE FDC* INTRODUCING OUR TELMISARTAN/ AMLODIPINE FDC* OFFERS 24 HOUR BLOOD PRESSURE CONTROL2 TELMISARTAN / AMLODIPINE 40/5 mg 40/10 mg 80/5 mg 80/10 mg CONVENIENTLY PACKED IN 30’s TESDYN 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg. Each tablet contains 40, 80 mg telmisartan respectively and 5, 10 mg amlodipine (as amlodipine besylate) respectively. S3 A55/7.1.3/0668, 0669, 0670, 0671. For full prescribing information, refer to the professional information approved by SAHPRA, November 2023. 1) Source: Based on internal analysis by Pharmadynamics (Pty) Ltd using data from the following source: IQVIA TPM MAT April 2024 ATC1 A1A- Brands measured in Units, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved 2) Approved professional information. * Fixed-dose combination. TNB1169/10/2024. CUSTOMER CARE LINE +27 21 707 7000 www.pharmadynamics.co.za ALWAYS ON GUARD
RkJQdWJsaXNoZXIy NDIzNzc=